Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1457-1464

  Buti, Maria ^a   Tsai, Naoky ^b   Petersen, Joerg ^c   Flisiak, Robert ^d   Gurel, Selim ^e   Krastev, Zahary ^f   Aguilar Schall, Raul ^g   Flaherty, John F ^g   Martins, Eduardo B ^g   Charuworn, Prista ^g   Kitrinos, Kathryn M ^g   Mani Subramanian, G ^g   Gane, Edward ^h   Marcellin, Patrick ⁱ  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e ULUDAG UNIVERSITY   (Turkey)

^f UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^g GILEAD SCIENCES   (United States)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ BEAUJON HOSPITAL   (France)

Author keywords

Antiviral agent; Cirrhosis; Hepatitis B e antigen; Liver disease

Indexed keywords

9-(2-((BIS(PIVALOYLOXYMETHOXY)PHOSPHINOYL)METHOXY)PROPYL)ADENINE; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN; PHOSPHOROUS ACID; VIRUS DNA;

ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ANTIVIRAL AGENTS; BIOMARKERS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PHOSPHOROUS ACIDS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84939650468     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3486-7     Document Type: Article

References (22)

1. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683.
2. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.
4. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther. 2005;10:431–439.
5. De Clercq E, Ferir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses. 2010;2:1279–1305.
6. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, de Clercq E, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother. 1994;38:2180–2182.
7. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
8. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
9. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2013;59:434–442.
10. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143.
11. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750–758.
12. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816.
13. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722.
14. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–1514.
15. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011;54:443–451.
16. Park JW, Kim HS, Seo DD, et al. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat. 2011;18:e475–e481.
17. Berg T, Zoulim F, Moeller B, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2014;60:715–722.
18. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2013;146:980–988.
19. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.
20. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16–22.
21. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–430.
22. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–S55.